Abivax: Maintaining 'Strong Buy' On Buyout Speculation And Obefazimod Advancement (ABVX)

Abivax (ABVX) rated Strong Buy: obefazimod’s phase 3 UC results, 2026 catalysts, and buyout talk.

You will be redirected in 10 seconds.

liveinternet liveinternet